Zobrazeno 1 - 10
of 198
pro vyhledávání: '"Roger, von Moos"'
Autor:
Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos
Publikováno v:
Bone Reports, Vol 22, Iss , Pp 101794- (2024)
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy
Externí odkaz:
https://doaj.org/article/c371b8c746ab4e2dabf3b1a2c7b4966c
Autor:
Tarun Mehra, Judith E Lupatsch, Thibaud Koessler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, Matthias E Schwenkglenks
Publikováno v:
PLoS ONE, Vol 19, Iss 12, p e0315976 (2024)
[This corrects the article DOI: 10.1371/journal.pone.0301271.].
Externí odkaz:
https://doaj.org/article/498eb1d4c69b49b0aff9e60200695c49
Autor:
Tarun Mehra, Judith E Lupatsch, Thibaud Kössler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, Matthias E Schwenkglenks
Publikováno v:
PLoS ONE, Vol 19, Iss 4, p e0301271 (2024)
ObjectiveTo assess the cost-effectiveness and budget impact of olaparib as a maintenance therapy in platinum-responsive, metastatic pancreatic cancer patients harboring a germline BRCA1/2 mutation, using the Swiss context as a model.MethodsBased on d
Externí odkaz:
https://doaj.org/article/1365e65c32554c52a26fd995ee151095
Autor:
Christoph Mamot, Andreas Wicki, Ursula Hasler-Strub, Salome Riniker, Qiyu Li, Lisa Holer, Daniela Bärtschi, Khalil Zaman, Roger von Moos, Konstantin J. Dedes, Laura A. Boos, Urban Novak, Alexandre Bodmer, Reto Ritschard, Ellen C. Obermann, Alexandar Tzankov, Christoph Ackermann, Véronique Membrez-Antonioli, Ursina Zürrer-Härdi, Clemens B. Caspar, Stefanie Deuster, Martin Senn, Ralph Winterhalder, Christoph Rochlitz
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis is poor and more than three quarters of patients experience progression 12 months after the initiation of conventional first
Externí odkaz:
https://doaj.org/article/1eb3fffffd304a00942ffdd17ebd7e8a
Autor:
Marcus Vetter, Karin M Rothgiesser, Qiyu Li, Hanne Hawle, Wolfgang Schönfeld, Karin Ribi, Salome Riniker, Roger von Moos, Andreas Trojan, Elena Kralidis, Mathias Fehr, Andreas Müller, Beat Thürlimann
Publikováno v:
Endocrine Oncology, Vol 2, Iss 1, Pp 9-18 (2023)
Objective: CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC50 4.4 nM) with antitumor effects against AR-positive tumor cells in vitro. This trial investiga
Externí odkaz:
https://doaj.org/article/ee02a98a152e445a96fded14df8d50d3
Autor:
Benjamin Kasenda, Miklos Pless, Beat Thürlimann, Stefanie Hayoz, Annina Lea Schenker, Christoph Kopp, Sämi Schär, Roger von Moos
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Background Premature trial discontinuation and non-publication of trial results are still major issues negatively affecting reliable evidence generation.Objectives To investigate trial completion and publication rate of cancer trials conducted within
Externí odkaz:
https://doaj.org/article/1cb4f34ae76b409fa5320de2cfdbe5d1
Autor:
Mirijam Nägeli, Joanna Mangana, Roger von Moos, Lukas Flatz, Robert E. Hunger, Rastine Merat, Olivier Gaide, Marco Siano, Reinhard Dummer
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 2, Iss 8, Pp 12-21 (2021)
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent type of non-melanoma skin cancer. Its incidence has been rising in recent years, with the highest rate reported in Switzerland compared to other countries in Europe. While the major
Externí odkaz:
https://doaj.org/article/97f9d504199f4c4898f1e6cdeb6edbcf
Autor:
Karin Ribi, Beat Thürlimann, Corinne Schär, Daniel Dietrich, Richard Cathomas, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Pierre Bohanes, Veronika Blum, Philippe von Burg, Meinrad Mannhart, Clemens B. Caspar, Roger von Moos, Michael Mark
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (Qo
Externí odkaz:
https://doaj.org/article/2f4e37bedf8d49deba6179a01a81e7f8
Autor:
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 2
Externí odkaz:
https://doaj.org/article/3a71b23e5f6e4fdeb49b83bd63c454c7
Autor:
Sandro T. Stoffel, Roger von Moos, Beat Thürlimann, Richard Cathomas, Silke Gillessen, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Anita Feller, Corinne Schär, Daniel Dietrich, Matthias Schwenkglenks, Judith E. Lupatsch, Michael Mark
Publikováno v:
Swiss Medical Weekly, Vol 151, Iss 0910 (2021)
BACKGROUND International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer (mCSPC) with bone metastas
Externí odkaz:
https://doaj.org/article/df3a8a388f13484995705aee9f4b2605